Microsponge Drug Delivery Systems: Advancing Methotrexate Delivery for Rheumatoid Arthritis Management

Clicks: 8
ID: 283885
2025
Article Quality & Performance Metrics
Overall Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
An estimated 23 million individuals worldwide suffer with rheumatoid arthritis, a debilitating inflammatory illness with a prevalence incidence of 0.5–1%. This chronic illness mostly affects synovial joints, causing inflammation, joint degeneration, and bone erosion. Patients suffer from a very low quality of life, and the condition has a significant socioeconomic impact. The pathophysiology of RA is caused by a complicated interaction between genetic and environmental variables that disrupt the control of the immune system. TNF-α, IL-6, and IL-1β are important inflammatory mediators that cause bone resorption and joint degeneration as the illness progresses. Microsponge drug delivery systems have been developed as a promising strategy to improve the therapeutic efficacy of methotrexate, which is a cornerstone in RA treatment. These systems offer controlled release, improved bioavailability, and targeted delivery to inflamed joints while minimizing systemic toxicity. Microsponge drug delivery systems can be formulated as topical gels, creams, patches, or injectable hydrogels, which allows for a variety of administration routes. Microsponge drug delivery systems are known for offering benefits of delivering methotrexate drugs by sustaining its release, providing reduced dosing, stability in the drug itself, and causing less side effect. Some challenges of microsponge drug delivery systems include a complicated manufacturing process, scalability issues, and regulatory problems that hamper its application in the clinic. In order to prove the safety and effectiveness of microsponge drug delivery systems, future research will concentrate on refining their composition, developing scalable production methods, and conducting extensive clinical studies. Innovation will keep developing, and by enhancing patient adherence, therapeutic results, and the quality of life for patients suffering from rheumatoid arthritis, microsponge drug delivery systems have the potential to completely transform the way this chronic illness is treated.
Reference Key
imported_1760441594_68ee34fabe364 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Smriti Gohri
Journal Current Pharmaceutical Research
Year 2025
DOI
10.63785/cpr.2025.1.1.1529
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.